Literature DB >> 9534972

Minimum protective serum concentrations of pneumococcal anti-capsular antibodies in infant rats.

A M Stack1, R Malley, C M Thompson, L Kobzik, G R Siber, R A Saladino.   

Abstract

Infant rats were passively immunized to determine the protective capacity of pneumococcal anticapsular antibodies. Animal-passaged strains of Streptococcus pneumoniae serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, and 23f were used as challenge inocula (1-1500 cfu) in a model of pulmonary infection that resulted in bacteremia, meningitis, and death. From untreated control animals, histologic sections of lung demonstrated infiltrative pneumonia and lung homogenate cultures grew S. pneumoniae at concentrations of 10(3)-10(8) cfu per gram of lung tissue. A type-specific anti-capsular antibody serum concentration of 0.1-1.15 microg/mL resulted in a statistically significant reduction in mortality compared with the reduction in untreated controls, except for serotype 14, which required 2.32 microg/mL for a significant reduction in mortality. The serum antibody level that provided 50% reduction in mortality ranged from 0.1-3.5 microg/mL for all serotypes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9534972     DOI: 10.1086/515259

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

1.  Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides.

Authors:  W R Usinger; A H Lucas
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 2.  Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Authors:  Catherine M Wernette; Carl E Frasch; Dace Madore; George Carlone; David Goldblatt; Brian Plikaytis; William Benjamin; Sally A Quataert; Steve Hildreth; Daniel J Sikkema; Helena Käyhty; Ingileif Jonsdottir; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

3.  Are the opsonophagocytic activities of antibodies in infant sera measured by different pneumococcal phagocytosis assays comparable?

Authors:  M Väkeväinen; W Jansen; E Saeland; I Jonsdottir; H Snippe; A Verheul; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

4.  Trojan horse effect: phagocyte-mediated Streptococcus iniae infection of fish.

Authors:  Amir Zlotkin; Stefan Chilmonczyk; Marina Eyngor; Avshalom Hurvitz; Claudio Ghittino; Avi Eldar
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

5.  Molecular and functional characteristics of a protective human monoclonal antibody to serotype 8 Streptococcus pneumoniae capsular polysaccharide.

Authors:  Z Zhong; T Burns; Q Chang; M Carroll; L Pirofski
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

6.  Effective combination therapy for invasive pneumococcal pneumonia with ampicillin and intravenous immunoglobulins in a mouse model.

Authors:  L De Hennezel; F Ramisse; P Binder; G Marchal; J M Alonso
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 7.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae.

Authors:  Tone Nordøy; Ingeborg S Aaberge; Anne Husebekk; Helvi H Samdal; Svein Steinert; Hasse Melby; Arne Kolstad
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

9.  Modification of bacteraemia by specific antibodies and relation with mortality in a pneumococcal mouse sepsis model.

Authors:  J Yuste; I Jado; M J Giménez; L Aguilar; F Molero; A Fenoll; J Casal
Journal:  Clin Exp Immunol       Date:  2002-06       Impact factor: 4.330

10.  Rapid decline of anti-pneumococcal antibody levels in nephrotic children.

Authors:  Ayfer Gür Güven; Sema Akman; Elif Bahat; Mustafa Senyurt; Selma Yüzbey; Aysen Uguz; Olcay Yegin
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.